NetFin Acquisition Corp. Files for a $220M IPO
by Kristi Marvin on 2019-07-12 at 10:15am

Well this is a pleasant surprise.  We had yet another new SPAC file to IPO last night, but this one has a FULL warrant.

Bucking the trend of half, third and even quarter warrants, NetFin Acquisition Corp. debuted their SPAC Thursday evening at $220 million and one WHOLE warrant.  Additional terms included 18 months, 100% in trust and a Crescent Term at $9.20. NetFin will be focusing on the Fintech sector and will be led by Martin Jaskel, as Executive Chairman, and Richard Maurer, as Chief Executive Officer and director.

As for Mr. Jaskel’s and Mr. Maurer’s backgrounds, their bios are all over the place and frankly, pretty difficult to read. In particular, Mr. Maurer’s, which seems to have an excessive amount of “action” words.  However, the take away seems to be that they both have a lot of experience working in finance.

However, going back to focusing on the terms, it almost feels shocking at this point to see a large SPAC come out with 18 months and a full warrant included in the unit.  This is because the last six SPACs to price have all been a 1/2 or 1/3 warrant deals, with the last two, large full-warrant SPACs to IPO being GigCapital2 and Proficient Alpha, back on June 6th and May 30th, respectively. And if we look back even further, the SPAC prior to those two that had a full warrant was Tuscan I, waaaay back on March 6th.  2019 has been absolutely dominated by very generous terms to management teams.  NetFin’s very investor friendly terms, on the other hand, look structured to SELL.  B. Riley ain’t playing around.

Additionally, the $220 million raise, as opposed to a $225 million raise, seems like an odd number but is perhaps a tip-off that they have a larger final size in mind.  Meaning, maybe they’re banking on an up-size to $260 million with an over-allotment to get them near the $300 million figure.  Or maybe they just like the number $220 million.

Again, SPAC investors have been on a pretty lean warrant diet, so NetFin feels like an “all you can eat” buffet.  It’s not a question of “will they be able to sell it”, but “how big will the book get”.

Summary of terms below:

Netfin term 7-12-19 v2

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved